| Hormone receptor-positive tumors (n=25) | Hormone receptor-negative tumors (n=17) | ||||||
---|---|---|---|---|---|---|---|---|
 | No. of Patients (No. of events) | 3-year estimates | 95% CI | P-value | No. of Patients (No. of events) | 3-year estimates | 95% CI | P-value |
All patients | 25 (7) | 0.76 | 0.58-0.95 | Â | 17 (5) | 0.69 | 0.42-0.95 | Â |
Response to neoadjuvant CT | Â | Â | Â | Â | Â | Â | Â | Â |
 pCR (grade 3) | 8 (1) | 0.81 | 0.58-1.05 | 0.485 | 12 (3) | 1.0 | - | 0.906 |
 No pCR (grade 0~2) | 14(4) | 0.77 | 0.49-1.05 |  | 3 (1) | 0.69 | 0.39-0.99 |  |
HER2 copy numbers | Â | Â | Â | Â | Â | Â | Â | Â |
 ≤ 2.0 | 6 (4) | 0.60 | 0.17-1.03 | 0.12 | 2 (1) | 0.50 | −0.19-1.19 | NA |
 > 2.0 | 19 (3) | 0.81 | 0.62-1.01 |  | 15 (4) | 0.74 | 0.47-1.00 |  |
Wild-type HER2 mRNA | Â | Â | Â | Â | Â | Â | Â | Â |
 < 400 | 14 (5) | 0.67 | 0.43-0.91 | 0.054 | 6 (3) | 0.33 | −0.17-0.83 | 0.196 |
 ≥ 400 | 6 (0) | 1.0 | - |  | 11 (2) | 0.86 | 0.60-1.12 |  |
∆16HER2 mRNA |  |  |  |  |  |  |  |  |
 < 4.5 | 14 (4) | 0.74 | 0.53-0.96 | 0.283 | 3 (1) | 0 | 0 | 0.832 |
 ≥ 4.5 | 6 (1) | 0.80 | 0.45-1.15 |  | 14 (4) | 0.72 | 0.45-1.00 |  |
Percentages of ∆16HER2 mRNA |  |  |  |  |  |  |  |  |
 < 2.4% | 17 (3) | 0.78 | 0.59-0.97 | 0.143 | 14 (3) | 0.77 | 0.49-1.00 | 0.073 |
 ≥ 2.4% | 3 (2) | 0.67 | 0.13-1.20 |  | 3 (2) | 0.33 | −0.20-0.87 |  |
PIK3CA (exons 9 and 20) | Â | Â | Â | Â | Â | Â | Â | Â |
 Wild-type | 21 (4) | 0.89 | 0.75-1.03 | 0.006 | 15 (5) | 0.65 | 0.37-0.94 | NA |
 Mutated | 4 (3) | 0.25 | −0.17-0.67 |  | 2 (0) | 1.0 | - |  |
PIK3CA (exons 9 and 20) | Â | Â | Â | Â | Â | Â | Â | Â |
 Wild-type + Norma l+ Loss +UPD | 16 (1) | 1.0 | - | 0.001 | 12 (5) | 0.57 | 0.25-0.89 | 0.2 |
 Mutated + Gain | 9 (6) | 0.40 | 0.06-0.74 |  | 5 (0) | 1.0 | - |  |
PTEN | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Gain + UPD | 20 (6) | 0.76 | 0.55-0.97 | 0.814 | 17 (5) | 0.69 | 0.42-0.95 | NA |
 Loss | 5 (1) | 0.80 | 0.45-1.15 |  | 0 | - | - |  |
INPP4B | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Gain + UPD | 21 (4) | 0.83 | 0.65-1.01 | 0.133 | 15 (4) | 0.75 | 0.49-1.00 | NA |
 Loss | 4 (3) | 0.50 | 0.01-0.99 |  | 2 (1) | 0.50 | −0.19-1.19 |  |
PI3KCA, PTEN, INPP4B | Â | Â | Â | Â | Â | Â | Â | Â |
 No aberrations* | 12 (0) | 1.0 | - | 0.002 | 10 (4) | 0.59 | 0.23-0.95 | 0.312 |
 Aberrations** | 13 (7) | 0.60 | 0.32-0.87 |  | 7 (1) | 0.75 | 0.33-1.17 |  |
DEK | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal | 17 (3) | 0.86 | 0.68-1.04 | 0.067 | 11 (2) | 0.91 | 0.74-1.08 | 0.106 |
 Gain | 8 (4) | 0.51 | 0.11-0.91 |  | 6 (3) | 0.30 | −0.17-0.77 |  |
FGFR1 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 17 (5) | 0.72 | 0.49-0.96 | 0.94 | 12 (4) | 0.59 | 0.28-0.91 | 0.69 |
 Gain | 8 (2) | 0.86 | 0.60-1.12 |  | 5 (1) | 1.0 | - |  |
CCND1 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 16 (2) | 0.91 | 0.74-1.08 | 0.075 | 9 (2) | 0.71 | 0.36-1.06 | 0.433 |
 Gain | 9 (5) | 0.51 | 0.16-0.85 |  | 8 (3) | 0.67 | 0.29-1.04 |  |
FOXA1 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + UPD | 17 (1) | 0.92 | 0.76-1.07 | 0.002 | 13 (5) | 0.66 | 0.39-0.93 | 0.504 |
 Gain | 8 (6) | 0.45 | 0.08-0.82 |  | 4 (0) | 1.0 | - |  |
CDH3 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 20 (3) | 0.88 | 0.73-1.04 | 0.007 | 17 (5) | 0.69 | 0.42-0.95 | NA |
 Gain | 5 (4) | 0.40 | −0.03-0.83 |  | 0 | - | - |  |
BIRC5 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 19 (3) | 0.86 | 0.68-1.04 | 0.016 | 8 (2) | 0.75 | 0.45-1.05 | 0.235 |
 Gain | 6 (4) | 0.44 | 0.01-0.88 |  | 9 (3) | 0.59 | 0.10-1.09 |  |
MYBL2 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 16 (2) | 0.92 | 0.78-1.07 | 0.015 | 14 (5) | 0.66 | 0.39-0.94 | 0.539 |
 Gain | 9 (5) | 0.48 | 0.11-0.84 |  | 3 (0) | 1.0 | - |  |
AIB1 | Â | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 17 (2) | 0.93 | 0.79-1.06 | 0.006 | 14 (5) | 0.66 | 0.39-0.94 | 0.539 |
 Gain | 8 (5) | 0.39 | −0.01-0.78 |  | 3 (0) | 1.0 | - |  |